Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in people with psoriatic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Sonelokimab (sonelokimab)

Snippet

Sponsor: MoonLake Immunotherapeutics AG | Conditions: Arthritis, Psoriatic | Phase 3 | Status: ENROLLING_BY_INVITATION